Mona Ashiya
CIK: 0001794070
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (39 total)
- Jul 27, 2026YARW
Yarrow Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
15.4K shares- - Jun 11, 2026STTK
Shattuck Labs, Inc.
Purchase(P)IndirectPre-Funded Warrants (right to buy)
1M shares- - Jun 11, 2026STTK
Shattuck Labs, Inc.
Purchase(P)IndirectPre-Funded Warrants (right to buy)
208.3K shares- - Jun 8, 2026STTK
Shattuck Labs, Inc.
Conversion(C)IndirectPre-Funded Warrants (right to buy)
15.4M shares- - Jun 8, 2026STTK
Shattuck Labs, Inc.
Conversion(C)IndirectCommon Warrants (right to buy)
3.1M shares- - Jun 8, 2026STTK
Shattuck Labs, Inc.
Conversion(C)IndirectCommon Warrants (right to buy)
15.4M shares- - Jun 8, 2026STTK
Shattuck Labs, Inc.
Conversion(C)IndirectPre-Funded Warrants (right to buy)
3.1M shares- - May 29, 2026STTK
Shattuck Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
81K shares- - Aug 28, 2025STTK
Shattuck Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
66.3K shares- - Aug 25, 2025STTK
Shattuck Labs, Inc.
Purchase(P)Indirect1.1M shares at avg. $0.87$912K - Aug 25, 2025STTK
Shattuck Labs, Inc.
Purchase(P)Indirect5.3M shares at avg. $0.87$4.6M - Jun 11, 2025IRON
Disc Medicine, Inc.
Award(A)DirectStock Option (Right to Buy)
10K shares- - Mar 24, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect2K shares at avg. $54.11$106K - Mar 24, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect3K shares at avg. $54.11$164K - Mar 24, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect756 shares at avg. $54.11$41K - Mar 21, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect3.4K shares at avg. $54.00$184K - Mar 21, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect5.3K shares at avg. $54.00$285K - Mar 21, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect1.3K shares at avg. $54.00$71K - Mar 20, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect364 shares at avg. $54.01$20K - Mar 20, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect941 shares at avg. $54.01$51K - Mar 20, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect1.5K shares at avg. $54.01$79K - Mar 19, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect13.5K shares at avg. $54.02$730K - Mar 19, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect5.2K shares at avg. $54.02$282K - Mar 19, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect20.9K shares at avg. $54.02$1.1M - Mar 12, 2025IRON
Disc Medicine, Inc.
Sale(S)Indirect42.9K shares at avg. $54.44$2.3M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 |  YARW Yarrow Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 15,435 | - | - | Direct |
| Jun 11, 2026 |  STTK Shattuck Labs, Inc. | Purchase(P) Pre-Funded Warrants (right to buy) | 1,041,667 | - | - | Indirect |
| Jun 11, 2026 | STTK Shattuck Labs, Inc. | Purchase(P) Pre-Funded Warrants (right to buy) | 208,333 | - | - | Indirect |
| Jun 8, 2026 | STTK Shattuck Labs, Inc. | Conversion(C) Pre-Funded Warrants (right to buy) | 15,366,490 | - | - | Indirect |
| Jun 8, 2026 | STTK Shattuck Labs, Inc. | Conversion(C) Common Warrants (right to buy) | 3,073,298 | - | - | Indirect |
| Jun 8, 2026 | STTK Shattuck Labs, Inc. | Conversion(C) Common Warrants (right to buy) | 15,366,490 | - | - | Indirect |
| Jun 8, 2026 | STTK Shattuck Labs, Inc. | Conversion(C) Pre-Funded Warrants (right to buy) | 3,073,298 | - | - | Indirect |
| May 29, 2026 | STTK Shattuck Labs, Inc. | Award(A) Stock Option (Right to Buy) | 81,000 | - | - | Direct |
| Aug 28, 2025 | STTK Shattuck Labs, Inc. | Award(A) Stock Option (Right to Buy) | 66,300 | - | - | Direct |
| Aug 25, 2025 | STTK Shattuck Labs, Inc. | Purchase(P) | 1,051,021 | $0.87 | $911,971 | Indirect |
| Aug 25, 2025 | STTK Shattuck Labs, Inc. | Purchase(P) | 5,255,106 | $0.87 | $4,559,855 | Indirect |
| Jun 11, 2025 |  IRON Disc Medicine, Inc. | Award(A) Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 1,956 | $54.11 | $105,839 | Indirect |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 3,026 | $54.11 | $163,737 | Indirect |
| Mar 24, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 756 | $54.11 | $40,907 | Indirect |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 3,412 | $54.00 | $184,248 | Indirect |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 5,279 | $54.00 | $285,066 | Indirect |
| Mar 21, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 1,320 | $54.00 | $71,280 | Indirect |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 364 | $54.01 | $19,660 | Indirect |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 941 | $54.01 | $50,823 | Indirect |
| Mar 20, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 1,457 | $54.01 | $78,693 | Indirect |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 13,517 | $54.02 | $730,188 | Indirect |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 5,228 | $54.02 | $282,417 | Indirect |
| Mar 19, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 20,911 | $54.02 | $1,129,612 | Indirect |
| Mar 12, 2025 | IRON Disc Medicine, Inc. | Sale(S) | 42,930 | $54.44 | $2,337,109 | Indirect |
1-25 of 39 transactions
About Ashiya Mona
Ashiya Mona (SEC CIK 0001794070) files insider reports with the SEC as Director of Yarrow Bioscience, Inc. (YARW), Director of Shattuck Labs, Inc. (STTK) and Director of Disc Medicine, Inc. (IRON).
Signal8 holds 12 ownership filings by Ashiya Mona (2 Form 3, 10 Form 4), filed between Mar 12, 2025 and Jul 29, 2026. Those filings report 39 transactions, from Mar 10, 2025 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ashiya Mona's filings is in NEW HAVEN, CT.
Recent filings by Ashiya Mona
- Jul 27, 2026: Grant or award of YARW derivative securities (Form 4, code A).
- Jun 11, 2026: Open-market purchases of STTK derivative securities (2 lines, Form 4, code P).
- Jun 8, 2026: Conversions of STTK derivative securities (4 lines, Form 4, code C).
- May 29, 2026: Grant or award of STTK derivative securities (Form 4, code A).
- Aug 28, 2025: Grant or award of STTK derivative securities (Form 4, code A).
Other insiders filing for Yarrow Bioscience, Inc. (YARW)
- Payton Lori, Chief Development Officer
- Alford Rachael, Chief Operating Officer
- Frey Rebecca, Chief Executive Officer
- Ryder Steven, Chief Medical Officer
- Zeronda Tyler, Chief Financial Officer
- RTW Fund Group GP, LLC, 10% Owner